Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

107
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
107
Positron Emission Tomography01:29

Positron Emission Tomography

4.2K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
4.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Monitoring glioblastoma dynamics during chemoradiation on the 1.5 T magnetic resonance imaging-linear accelerator.

Clinical and translational radiation oncology·2026
Same author

A Phase 1 and Biodistribution study of Ifabotuzumab, a humanized agonistic EphA3-targeted antibody, in patients with recurrent glioblastoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Identifying factors associated with sleep disturbance among adults seeking outpatient psychiatric services for anxiety and related disorders.

Bulletin of the Menninger Clinic·2026
Same author

Cancer workforce-a global crisis: a Lancet Oncology Commission.

The Lancet. Oncology·2026
Same author

Estimating total and diagnosed global cancer incidence and stage distribution from 1990 to 2050: a simulation-based analysis of 17 cancers.

The Lancet. Oncology·2026
Same author

Estimating global cancer survival and mortality from 1990 to 2050: a simulation-based analysis of 17 cancers.

The Lancet. Oncology·2026

Related Experiment Video

Updated: Jun 25, 2025

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules
09:55

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules

Published on: October 4, 2024

351

Production and regulatory issues for theranostics.

Francesco Giammarile1, Diana Paez1, Richard Zimmermann2

  • 1Division of Human Health, Department of Nuclear Safety and Security, International Atomic Energy Agency, Vienna, Austria.

The Lancet. Oncology
|May 31, 2024
PubMed
Summary
This summary is machine-generated.

Theranostics, a key cancer therapy, faces access challenges globally. This paper examines supply and regulatory hurdles impacting the availability of radiopharmaceuticals for patients with neuroendocrine tumors and prostate cancer.

More Related Videos

Enhancing Efficiency and Radiolabeling Yields of Carbon-11 Radioligands for Clinical Research Using the Loop Method
09:08

Enhancing Efficiency and Radiolabeling Yields of Carbon-11 Radioligands for Clinical Research Using the Loop Method

Published on: December 20, 2024

1.3K
A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
08:55

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

Published on: April 17, 2019

17.6K

Related Experiment Videos

Last Updated: Jun 25, 2025

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules
09:55

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules

Published on: October 4, 2024

351
Enhancing Efficiency and Radiolabeling Yields of Carbon-11 Radioligands for Clinical Research Using the Loop Method
09:08

Enhancing Efficiency and Radiolabeling Yields of Carbon-11 Radioligands for Clinical Research Using the Loop Method

Published on: December 20, 2024

1.3K
A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
08:55

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

Published on: April 17, 2019

17.6K

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Radiopharmaceutical Therapy

Background:

  • Theranostics has significantly advanced cancer care in the past decade.
  • Approved theranostic agents are now available for neuroendocrine tumors and prostate cancer.
  • Global access to these innovative treatments is crucial for patient benefit.

Purpose of the Study:

  • To explore factors affecting the accessibility and availability of theranostic radiopharmaceuticals.
  • To identify supply chain and regulatory challenges impacting theranostic treatment delivery.
  • To ensure equitable global access to advanced cancer therapies.

Main Methods:

  • Review of current literature on theranostic radiopharmaceutical supply chains.
  • Analysis of regulatory landscapes impacting radiopharmaceutical approval and distribution.
  • Case study examination of access issues in different global regions.

Main Results:

  • Significant disparities exist in global access to theranostic radiopharmaceuticals.
  • Supply chain complexities and manufacturing limitations hinder widespread availability.
  • Varying national regulatory frameworks create barriers to treatment adoption.

Conclusions:

  • Addressing supply and regulatory challenges is essential for expanding theranostic benefits.
  • International collaboration is needed to harmonize regulations and improve supply chains.
  • Ensuring global access to theranostic radiopharmaceuticals is critical for equitable cancer care.